

RESEARCH

Open Access



Chm-1 gene-modified bone marrow mesenchymal stem cells maintain the chondrogenic phenotype of tissue-engineered cartilage

Zhuoyue Chen^{1,2†}, Jing Wei^{1†}, Jun Zhu¹, Wei Liu¹, Jihong Cui^{1,2}, Hongmin Li^{1,2} and Fulin Chen^{1,2*}

Abstract

Background: Marrow mesenchymal stem cells (MSCs) can differentiate into specific phenotypes, including chondrocytes, and have been widely used for cartilage tissue engineering. However, cartilage grafts from MSCs exhibit phenotypic alternations after implantation, including matrix calcification and vascular ingrowth.

Methods: We compared chondromodulin-1 (Chm-1) expression between chondrocytes and MSCs. We found that chondrocytes expressed a high level of Chm-1. We then adenovirally transduced MSCs with *Chm-1* and applied modified cells to engineer cartilage in vivo.

Results: A gross inspection and histological observation indicated that the chondrogenic phenotype of the tissue-engineered cartilage graft was well maintained, and the stable expression of Chm-1 was detected by immunohistological staining in the cartilage graft derived from the Chm-1 gene-modified MSCs.

Conclusions: Our findings defined an essential role for Chm-1 in maintaining chondrogenic phenotype and demonstrated that Chm-1 gene-modified MSCs may be used in cartilage tissue engineering.

Keywords: Chondromodulin-1, Mesenchymal stem cells, Chondrocytes, Cartilage tissue

Background

Cartilage regeneration and repair is often needed in orthopedic or plastic and reconstructive surgery for the treatment of cartilaginous defects and malformations. Unlike other self-repairing tissues, cartilage is an avascular tissue characterized by a low cell density and limited nutrient supply [1, 2]. Because of the limited regenerative capacity of cartilage, the treatment of various cartilaginous lesions remains a challenge to clinicians.

Tissue engineering provides an optimized alternative for cartilage regeneration and repair by combining chondrogenic cells and a scaffold [3, 4]. Chondrocytes are most commonly used for cartilage tissue engineering. However, the harvesting of a cartilage biopsy to obtain

primary chondrocytes may cause donor site morbidity, and chondrocytes will dedifferentiate and lose their chondrogenic phenotype during monolayer expansion [5]. Compared with chondrocytes, marrow mesenchymal stem cells (MSCs) could be easily isolated, expanded, and directed to differentiate into mesodermal lineages, including bone, cartilage, and adipose tissue [6, 7]. MSCs may undergo chondrogenic differentiation with the induction of transforming growth factor beta (TGF- β), especially under micropellet culture condition [8], and great efforts have been made to use MSCs for cartilage tissue engineering [9–11]. However, cartilage grafts from MSCs undergo gradual histological changes after implantation, including chondrocyte hypertrophy, extracellular matrix calcification, and vascular invasion, which may significantly influence the treatment outcome of cartilage defects [12, 13].

Coculturing with chondrocytes was usually employed to maintain the stable chondrogenic phenotype of MSCs.

* Correspondence: chenfl@nwu.edu.cn

†Equal contributors

¹Laboratory of Tissue Engineering, Faculty of Life Science, Northwest University, 229 TaiBai North Road, Xi'an, Shaanxi Province 710069, P.R. China

²Provincial Key Laboratory of Biotechnology of Shaanxi, Northwest University, 229 TaiBai North Road, Xi'an, Shaanxi Province 710069, P.R. China

The approach could improve collagen type II and glycosaminoglycan expression as well as the deposition of MSCs. The mechanism was attributed to signaling via direct cell–cell contacts [14–16] and paracrine factors secreted by chondrocytes [17, 18]. Kang et al. [19] demonstrated that a 1:1 ratio of chondrocytes to MSCs can be used to engineer phenotypically stable cartilage, and obvious vascular invasion could not be observed 6 weeks after in-vivo implantation. However, engineering cartilage with co-seeding of chondrocytes and MSCs still requires the surgical harvesting of cartilage biopsy to obtain chondrocytes [20].

Chondromodulin-1 (Chm-1) is a glycoprotein with 25 kDa molecular weight and is found highly expressed in cartilage tissue [21]. Chm-1 could inhibit the endothelial cell proliferation and tube morphogenesis, induce apoptosis of vascular endothelial cells in vitro, as well as inhibit angiogenesis in the chick chorioallantoic membrane [22–24]. Mature cartilage contains considerable amounts of Chm-1, is avascular, and its extracellular matrix does not calcify. Meanwhile healing cartilage from MSCs within the cartilage lesions of the knee joint lacked Chm-1 expression, and exhibited excessive ossification and vascularization [25]. Based on these findings, we may deduce that the phenotypic drift of cartilage grafts from MSCs after in-vivo implantation is due to the low expression of Chm-1 in MSCs.

In the current experiment, we first compared Chm-1 expression profiles in MSCs and chondrocytes. We then engineered phenotypically stable cartilage grafts from Chm-1 gene-modified MSCs. Coral has an interconnected porous structure and good osteoconductive activity which are suitable for blood vessel invasion and tissue ossification [26–28]. We chose coral as the cell-seeding scaffold to investigate the critical effect of Chm-1 on anti-vascularization and maintaining the chondrogenic phenotype of tissue-engineered cartilage with MSCs.

Methods

All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified.

Isolation and culture of MSCs and chondrocytes

Rabbit MSCs were isolated and cultured as reported previously [28]. New Zealand rabbits (1 month old) were obtained from the animal holding unit of Four Military Medical University (FMMU, Xi'an, Shaanxi Province, P.R. China) and samples of bone marrow were harvested in accordance with IACUC approval from Northwest University, Xi'an, P.R. China. Briefly, the obtained marrow was suspended and cultured in Dulbecco's modified Eagle medium (DMEM; Gibco BRL, Grand Island, NY, USA) containing 10 % fetal bovine serum (FBS), 272 µg/ml L-glutamine, and 100 U/ml penicillin/streptomycin. The

media were changed every 3 days. Before the cells formed a confluent monolayer, they were digested using trypsin 0.25 % and harvested by centrifugation, and cells of passage 2 were used for the experiment. The cell density was adjusted to 5×10^7 cells/ml with medium before cell seeding.

Rabbit chondrocytes were isolated and cultured according to the method described by Wu et al. [29]. All New Zealand rabbits were anesthetized with ketamine (40 mg/kg, intramuscularly) and xylazine (5 mg/kg, intramuscularly). After aseptic preparation, the auricle cartilage from ear roots was dissected and cut into pieces of approximately 2 mm³ after being rinsed three times with phosphate-buffered saline (PBS) supplemented with 100 U/ml penicillin and 100 U/ml streptomycin; the cartilage samples were digested with 0.2 % collagenase type II (Gibco) in DMEM (Gibco) at 37 °C for 12 hours. The digested cell suspension was filtered through a 250 µm nylon mesh filter to remove matrix debris and was centrifuged at 1000 rpm for 5 minutes; the resulting cell pellet was washed twice with PBS and resuspended with DMEM containing 10 % FBS, L-glutamine (272 µg/ml), and ascorbic acid (5 µg/ml). The medium was changed every 3 days. The chondrocytes were subcultured twice, collected by trypsin digestion, and suspended in culture medium at a density of 5×10^7 cells/ml for seeding.

RNA isolation and reverse transcription-PCR

The expression levels of *Chm-1*, *Col II*, and *AGG* in chondrocytes and MSCs were compared by reverse transcription-PCR (RT-PCR). Total RNA was isolated from chondrocytes and MSCs using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). For cDNA synthesis, RT-PCR was performed using the Takara RT-PCR Kit (Takara, Dalian, China). The reaction product cDNA was used as a template for PCR amplification. The PCR conditions were as follows: initial denaturation at 94 °C for 3 minutes; 30 cycles at 94 °C for 40 seconds, 60 °C for 40 seconds, and 72 °C for 80 seconds; and a final extension at 72 °C for 5 minutes. The PCR products were visualized on 1.5 % agarose gels. *GAPDH* was used as an internal control. The primer sequences used for this analysis are presented in Table 1. Band intensity was quantified using BandsScan software. The gray values of bands were normalized relative to those of *GAPDH*. The gray values were expressed in relation to the control and presented as means ± SD from four independent experiments.

Western blot analysis

Western blot analysis was carried out for Chm-1, Col II, and AGG expression of MSCs and chondrocytes. Equal amounts of protein extracts (30 µg/lane) were separated

Table 1 Primer sequences for reverse transcription-PCR

Gene	Primers	Product size (base pairs)
<i>GAPDH</i>	TCACCATCTTCCAGGAGCGA	293
<i>AGG</i>	CACAATGCCGAAGTGGTCGT GGTCGTGGTGAAAGGTGTTGT	315
<i>Col II</i>	GCAGACGCATGAAGGCAAGTT AGCAGCAGCACGTGTGGTT	97
<i>Chm-1</i>	ATCTGGACGTTGGCAGTGTG CCGCTCGAGCATGACCGAGAAGTCTGGACA CCGGAATTCGCACCTGATACGCAAAGTGA	1022

by SDS-PAGE and transferred to the nitrocellulose membrane. Nonspecific binding was blocked with TBS buffer (50 mM Tris/HCl and 150 mM NaCl) containing 5 % (w/v) skimmed milk for 2 hours at room temperature. The membranes were then incubated with primary antibodies (1:1000 (v/v) for GAPDH, 1:1000 (v/v) for Chm-1, 1:1000 (v/v) for Col II, and 1:1000 (v/v) for AGG; Santa Cruz, Santa Cruz, California, USA) for 2 hours at 37 °C. After washing with TBS containing 0.05 % Tween-20 (TBST) three times, the membranes were incubated for 1 hour at 37 °C with secondary antibodies conjugated with horseradish peroxidase diluted 1:1000 in TBST. Finally, the membranes were treated with enhanced chemoluminescence (ECL) reagent (Santa Cruz) and exposed to Kodak X-ray film. GAPDH acted as internal control.

MSCs modified with *Chm-1* gene

Chm-1 cDNAs were amplified from rabbit chondrocytes by PCR using the primers presented in Table 1. The PCR products were subcloned into the pDC316 expression adenovirus vector (pDC316-*Chm-1*) after restriction enzyme digestion. According to the manufacturer's instructions for the AdMax Kit D (Microbix Biosystems Inc., Toronto, ON, Canada), HEK 293 producer cells were cotransfected with pBHGlox E1, 3Cre, and expression adenovirus vector (pDC316-*Chm-1*) to obtain the adenovirus-containing *Chm-1* gene (Ad5-*Chm-1*).

Second-passage rabbit MSCs were transduced with an adenovirus containing either green fluorescent protein (GFP) (Ad5-GFP) or *Chm-1* (Ad5-*Chm-1*) for 72 hours at a multiplicity of infection (MOI) of 1000 plaque-forming units (PFU)/cell. The efficiency of adenovirus gene transfer in MSCs was evaluated under a fluorescence microscope 72 hours after transfection.

Expression of *Chm-1* in Ad5-*Chm-1*-transfected MSCs

Total RNA was isolated from MSCs before infection and 72 hours after infection using TRIzol Reagent (Invitrogen). For cDNA synthesis, the total RNA was reverse-transcribed using the Takara RT-PCR Kit for RT-PCR. The reaction product cDNA was used as a template for PCR amplification. The PCR conditions were as follows: initial denaturation at 94 °C for 3 minutes; 30 cycles at

94 °C for 40 seconds, 60 °C for 40 seconds, and 72 °C for 80 seconds; and a final extension at 72 °C for 5 minutes. PCR products were visualized on 1.5 % agarose gels. *GAPDH* was used as the internal control. The primer sequences used for this analysis are presented in Table 1. The gray values of bands were normalized relative to those of *GAPDH*. The gray values were expressed in relation to the control and presented as means \pm SD from four independent experiments. To confirm the bioactivity of transgenic *Chm-1*, the expression levels of *Chm-1*, Col II, and AGG in Ad5-*Chm-1*-transfected MSCs (T-MSCs) were measured by western blot analysis. The western blot analysis was carried out as described previously. Furthermore, the *Chm-1* and Col II proteins were detected by immunofluorescence. Briefly, the MSCs, chondrocytes, and T-MSCs were washed three times with PBS (pH 7.4). Cells were fixed for 10 minutes by incubating in 4 % formaldehyde in PBS followed by further washing and preincubation with 1 % bovine serum albumin (BSA) for 30 minutes. Incubation was with anti-*Chm-1* antibody (Santa Cruz) and anti-Col II antibody (Santa Cruz) for 20 minutes at room temperature. Next, the samples were rinsed in PBS followed by incubation with Cy3-conjugated antimouse secondary antibody (Calbiochem, Darmstadt, Germany) for 20 minutes at room temperature, PBS washing, and finally staining with 5 mg/ml Hoechst 33342 for 30 minutes. The fluorescence images from stained samples were obtained using a confocal laser scanning microscope (FV1000; Olympus Corporation, Tokyo, Japan).

Construction of cell-scaffold complex

Natural coral (*Gonophoresduofaciata*, Hainan, China) was carefully molded into the shape of a tube that was 8 mm in diameter and 2 mm thick. The material was treated as described previously [30]. Briefly, it was immersed in 50 mg/ml sodium hypochlorite for 14 days, and the medium was changed every other day to remove foreign protein in the coral. The scaffold was then washed with distilled water and autoclaved before use.

In preparation for cell seeding, empty scaffolds were prewetted in culture medium for 10 minutes. Cells were then pipetted onto each scaffold to achieve a final seeding number of 2×10^6 cells in 40 μ l suspensions. Each scaffold was seeded with cells which were

i) chondrocytes, ii) 1:1 mixture of MSCs and chondrocytes, iii) MSCs, and iv) T-MSCs. The cell–scaffold complexes were placed into dishes and moved to the incubator for 4 hours to ensure that most cells adhered to the scaffolds. Then, 2 ml of medium was carefully added around the complexes. Twelve hours later, an additional 10 ml of medium was added. The composites were then incubated for 5 days to allow for cell attachment. Prior to implantation, the scaffolds were rinsed in sterile PBS, stained with Hoechst 33342, and observed through a fluorescence microscope (Nikon, Tokyo, Japan). Twelve hours and 5 days after cell seeding, a PicoGreen DNA quantitation assay [31] was used to monitor cell-seeding efficacy and proliferation on coral scaffolds ($n = 4$). The DNA quantitation of 2×10^6 cells before seeding acted as controls.

Subcutaneous implantation in nude mice

Eight BALB/c nude mice (6 weeks old, from the animal holding unit of FMMU) were used for the experiment. The animals were acclimated for 1 week before the surgery and monitored for general appearance, activity, excretion, and weight. All procedures were approved by the IACUC of Northwest University. Before implantation, the nude mice were anesthetized by intraperitoneal injection of 10 % chloral hydrate (300 mg/kg). After aseptic preparation, the skin on the back was incised and a subcutaneous pocket was made. The coral–implant composite scaffolds loaded with cells (four kinds of composites: scaffold loaded with i) chondrocytes, ii) 1:1 chondrocytes and MSCs, iii) MSCs, and iv) T-MSCs) were implanted into eight animals (each animal received four kinds of implant). After 1 and 2 months of implantation, the animals ($n = 4$, at each time point) were sacrificed by neck dislocation and specimens were harvested. The specimens were observed by gross inspection and then fixed with 10 % phosphate-buffered formalin.

Analyses of Chm-1 distribution and vascularization in newly formed tissue

After the specimens were fixed in 10 % phosphate-buffered formalin for 24 hours and demineralized in 5 % formic acid for 5 days, they were dehydrated in graded alcohols and embedded in paraffin before preparing sections 7 μ m thick. The sections were stained with hematoxylin and eosin (H & E) and toluidine blue (TB) to evaluate the cartilaginous matrix. Finally, Masson's trichrome staining (MTS) was utilized to detect the vascular structure [32].

Immunofluorescence was performed using the following primary antibodies: anti-Col II antibody (Santa Cruz) and anti-Chm-1 antibody (Santa Cruz). All incubations were performed in a humidified chamber. Next, the sections were rinsed in PBS followed by incubation with FITC-conjugated antimouse secondary antibody (Calbiochem).

Finally, the sections were examined using a fluorescence microscope.

The blood vessel density was quantitatively analyzed from MTS of representative sections from each specimen. Vessels were identified by their luminal structure and the presence of red blood cells stained yellow within their boundaries. Vessels were counted from four random fields of each section under 200 \times magnification as the vessel number in each specimen. The vessel density in each group was determined by the average number of blood vessels from specimens ($n = 4$).

Statistical analysis

Results are reported as the mean \pm SD, and significance was determined using a probability value of $P < 0.05$. The significance of differences between groups was assessed using a two-way analysis of variance (ANOVA) with Tukey's post-hoc analysis.

Results

Different expression of *Chm-1* gene in chondrocytes and MSCs

According to the RT-PCR results, both chondrocytes and MSCs expressed genes encoding cartilage-specific matrix proteins, including *Col II* (97 base pairs (bp)) and *AGG* (315 bp) (Fig. 1a). Importantly, high *Chm-1* gene (1000 bp) expression was found in chondrocytes, whereas expression of *Chm-1* gene was low in MSCs (Fig. 1a). Furthermore, Chm-1, Col II, and AGG protein levels were also measured using western blot. As shown in Fig. 1b, Chm-1 protein was specifically expressed in chondrocytes at a level higher than that of MSCs ($P < 0.01$). Immunofluorescence tests further demonstrated that the expression of Chm-1 differed in chondrocytes and MSCs (Fig. 1c). The result demonstrated that Chm-1 was specifically expressed in chondrocytes.

Transfection of MSCs with *Chm-1* gene

As shown in Fig. 1a, the *Chm-1*, *Col II*, and *AGG* genes were detected by RT-PCR in the T-MSCs, whereas the expression of *Chm-1* gene was very low in the untransfected MSCs. To further confirm chondrogenic phenotype on a protein level, Chm-1, Col II, and AGG protein levels were also measured using western blot. As shown in Fig. 1b, Chm-1 was specifically expressed in T-MSCs at a level higher than that of untransfected MSCs ($P < 0.01$). Meanwhile, Col II and AGG were significantly expressed in T-MSCs at levels higher than those of MSCs ($P < 0.01$). An immunofluorescence observation (Fig. 1c) indicated that T-MSCs expressed Chm-1 and Col II, whereas no staining could be observed in untransfected MSCs. These findings indicated that adenovirus-mediated transfection successfully generated Chm-1 gene-modified MSCs.




Fig. 1 (See legend on next page.)

(See figure on previous page.)

Fig. 1 a RT-PCR evaluation of *Chm-1*, *Col II*, and *AGG* gene expression in chondrocytes, MSCs, and T-MSCs cultured in vitro. *GAPDH* was used as an internal control. Intensity levels showing *Chm-1*, *Col II*, and *AGG* mRNA expression levels in T-MSCs and chondrocytes were significantly higher than those of MSCs (** $P < 0.01$, mean \pm SD, $n = 4$). **b** Western blot assay for *Chm-1*, *Col II*, and *AGG* expression. *Chm-1*, *Col II*, and *AGG* expression were significantly upregulated in T-MSCs and chondrocytes. Analysis of band intensities indicated that *Chm-1*, *Col II*, and *AGG* expression levels higher in T-MSCs and chondrocytes than the levels in MSCs (** $P < 0.01$, mean \pm SD, $n = 4$). **c** Immunofluorescence examination showed cell transduction efficiency 5 days after transduction. *Chm-1* and *Col II* protein expression was evaluated by immunofluorescence examination. Data are represented as mean \pm standard deviation from four independent sets of experiments. * $P \leq 0.05$, ** $P \leq 0.01$, and *** $P \leq 0.001$ BMSC bone marrow mesenchymal stem cell, *Chm-1* Chondromodulin-1, T-BMSC Ad5-*Chm-1* transfected BMSC

Construction of cell–scaffold complex

The coral scaffold is shown in Fig. 2a. Approximately 2×10^6 cells were seeded on each coral scaffold to form a cell–scaffold complex (Each scaffold loaded with i) chondrocytes, ii) 1:1 mixture of MSCs and chondrocytes, iii) MSCs, and iv) T-MSCs, respectively.). According to Fig. 2c, cell-seeding efficiency was around 75–78 %, and cells proliferated 1.32–1.45 times on coral scaffolds 5 days after seeding in each group. There were no significant differences among groups. Cell nuclei were stained with Hoechst 33342 and visualized by fluorescence microscope. The fluorescent micrographs (Fig. 2b) indicated that the internal structure of the coral scaffold was porous, and that cells were evenly distributed throughout the coral scaffolds. The results indicated that the scaffold was biocompatible and able to support the initial attachment and subsequent proliferation of MSCs in vitro.

In-vivo evaluation of the tissue-engineered cartilage

Figure 2d shows the gross appearance of specimens from different groups 1 and 2 months after implantation. Specimens from the chondrocyte-seeding (Fig. 2d,i) and chondrocyte–MSC-coseeding (Fig. 2d,ii) groups appeared light red. Specimens from the MSC-seeding group (Fig. 2d,iii) were dark red, and a thin layer of soft tissue and blood vessels could be observed clearly on the surfaces of the specimens. In contrast, specimens from the *Chm-1*-transfected MSCs (Fig. 2d,iv) could be separated easily from the adherent fibrous capsule and were light red.

H & E staining, TB staining, and MTS were performed to examine the tissue formation and vessel density in the scaffolds. H & E staining, TB staining, and MTS observation did not reveal obvious vascularization and bone formation in the chondrocyte-seeding (Fig. 3a) and chondrocyte–MSC-coseeding (Fig. 3b) groups. However, TB staining showed mature bone formation via endochondral ossification in scaffolds seeded only with MSCs (Fig. 3c, arrow), and MTS results (Fig. 3c) revealed active vascularization (arrow) in these specimens. By contrast, a large amount of mature cartilage formed in the pores of the coral scaffold, and bone formation and vascularization were not evident in the T-MSC specimens (Fig. 3d).

Expression of the chondrogenic-specific proteins *Col II* and *Chm-1* was evaluated by immunohistology. As

showed in Fig. 4, *Col II* (green fluorescence) and *Chm-1* (green fluorescence) expression were evident in the chondrocyte-seeding (Fig. 4a) and chondrocyte–MSC-coseeding (Fig. 4b) groups but rarely in scaffolds seeded only with MSCs (Fig. 4c). The T-MSCs expressed abundant *Col II* (green fluorescence) and *Chm-1* (green fluorescence), which was evenly distributed throughout the cells (Fig. 4d).

MTS-stained vessels were observed in the specimens after implantation for 1 and 2 months (Fig. 5). The blood vessel density of both groups continuously increased 1–2 months after implantation. Compared with the specimens seeded with MSCs (1 month 47.25 ± 3.59 ; 2 months 43.00 ± 4.24), the mean blood vessel densities in the chondrocyte–MSC-coseeding groups (1 month 4.50 ± 0.67 ; 2 months 12.25 ± 2.58) were significantly reduced at each time point ($P < 0.05$). The mean blood vessel density in the chondrocytes:MSCs = 1:1 group did not significantly differ from that in the chondrocyte-seeding group (1 month 4.25 ± 0.53 ; 2 months 8.00 ± 0.82 ; $P > 0.05$). MTS indicated that the mean blood vessel density in the T-MSC-seeding group (1 month 9.58 ± 1.85 ; 2 months 10.08 ± 1.64) was significantly lower than that in the MSC-seeding group (1 month 47.25 ± 3.59 ; 2 months 43.00 ± 4.24) at each time point ($P < 0.05$).

Discussion

MSCs could undergo chondrogenic differentiation in the presence of the appropriate growth factors and has been considered an attractive cell source for cartilage tissue engineering [8]. However, tissue-engineered cartilage constructed by chondrogenic induction of MSCs exhibits a hypertrophic phenotype and extensive calcification of the extracellular matrix after implantation [12, 13]. Mueller and Tuan [33] reported that the combination of TGF- β withdrawal, dexamethasone reduction, and thyroid hormone addition could induce hypertrophy of chondrogenic induced MSCs, accompanied by increased alkaline phosphatase activity, matrix mineralization, and changes in hypertrophy markers. They concluded that chondrogenically induced MSCs were functionally similar to growth plate chondrocytes, which underwent a differentiation program analogous to endochondral ossification. Vascular invasion is a histological marker of




Fig. 2 **a** Natural coral scaffolds (8 mm in diameter and 2 mm in height). **b** T-MSCs and coral scaffold complex. Fluorescence microscope examination showed the attachment of T-MSCs on the coral scaffold. Nuclei were visualized by Hoechst 33342 staining. **c** Cell-seeding efficacy and proliferation on coral scaffolds ($n = 4$). Each scaffold was seeded with 2×10^6 cells which were *i* chondrocytes, *ii* 1:1 mixture of MSCs and chondrocytes, *iii* MSCs, and *iv* T-MSCs. The initial 2×10^6 cells before seeding from each group acted as control. There were no significant differences among groups ($P > 0.05$). **d** Representative macroscopic pictures of the cell-scaffold composites (*i* chondrocyte-coral composites, *ii* chondrocytes and MSCs coseeded into natural coral scaffolds in ratio of 1:1, *iii* MSC-coral composites, and *iv* T-MSC-coral composites) removed from animals after 1 month and 2 months (Color figure online)

endochondral ossification, and previous studies show that the degree of vascularization significantly differs between cartilage engineered with chondrocytes and cartilage engineered with MSCs [34], which indicate that the regulation of vascular formation may differ greatly between chondrocytes and MSCs. These drawbacks may significantly influence the treatment of cartilage defects with MSCs. Chm-1 is specifically expressed in the avascular area of some mesenchymal tissues, including certain ocular tissues, cardiac valve, and cartilage [23, 35–38]. Chm-1 has been demonstrated to inhibit angiogenesis, and many studies investigate the effects of Chm-1 and the

mechanisms by which it inhibits angiogenesis and disrupts the vasculature [39–41].

Microfracturing of the subchondral bone plate is a frequently employed approach in the clinic. The approach could guide MSCs to migrate into the defect to improve cartilage lesion repair [42]. Blanke et al. [25] reported that cartilage healing from microfracturing lacked the expression of Chm-1, and was associated with excessive matrix calcification and vascular ingrowth. And that additional transplantation of chondrocytes could significantly prevent matrix calcification and vascular ingrowth. In agreement with Blanke et al.'s study, we found that MSCs




Fig. 3 Histologic analyses in chondrogenically differentiated cells and the vascularization in newly formed tissue in vivo. The specimens were transplanted into nude mice. Appearance of specimens 1 month and 2 months post transplantation for **a** chondrocyte-coral composites, **b** chondrocytes and MSCs coseeded into natural coral scaffolds in a ratio of 1:1, **c** MSC-coral composites, and **d** T-MSC-coral composites. The specimens were processed for histologic staining with H & E, TB, and MTS. Red arrows indicate endochondral ossification. Black arrows indicate vascular structures. H&E hematoxylin and eosin, MTS Masson's trichrome staining, TB toluidine blue (Color figure online)

expressed cartilage-specific genes including *Col II* and *AGG* (Fig. 1), however, unlike chondrocytes which expressed high levels of *Chm-1*, the expression of *Chm-1* was very low in MSCs (Fig. 1). This finding further demonstrated that native MSCs are not optimized cells for cartilage regeneration.

We then transfected MSCs with Ad5-Chm-1. Interestingly, transfected MSCs not only expressed a high level of Chm-1 but the expression of cartilage-specific genes was also significantly upregulated (Fig. 1). Previous studies have indicated that coculturing MSCs with chondrocytes leads to increased chondrogenic gene expression and ECM deposition in MSCs, and these phenotypic changes are considered to be the result of growth factors secreted by chondrocytes [43, 44]. According to the result of our study, Chm-1 is also a signaling molecule that regulates chondrogenic phenotype of MSCs.

Finally, we fabricated cartilage grafts with Chm-1-transfected MSCs. In this experiment, we used porous coral as a cell-seeding scaffold, which facilitates the vascularization and ossification of engineered tissue [45, 46]. The result showed that mature cartilage formed in the pores of the scaffold, and bone formation was not observed in the specimens 2 months after implantation (Figs. 2, 3, 4). The newly formed tissue also exhibited strong immunohistochemical staining for Chm-1. However, a large amount of bone and marrow tissue formed in the MSC-seeding group 2 months after implantation (Figs. 2, 3, 4). Importantly, the number of blood vessels in the engineered graft was similar to that in the chondrocyte-seeding group ($P > 0.05$) and significantly lower than that in the MSC-seeding group ($P < 0.05$) (Fig. 5). Klinger et al. [47] transfected osteochondral progenitor cells with Chm-1 and subsequently transplanted




Fig. 4 Analysis of chondrogenic protein expression for neocartilage formation in the specimens. The specimens were transplanted into nude mice. Specimens 1 and 2 months post transplantation: **a** chondrocyte-coral composites; **b** chondrocytes and MSCs coseeded into natural coral scaffolds in a ratio of 1:1; **c** MSC-coral composites; and **d** T-MSC-coral composites. Specimens were processed to analyze the distribution of Col II (green) and Chm-1 (green) in cells by immunofluorescence (Color figure online)

cells into cartilage lesions of a joint and found that transfected osteochondral progenitor cells maintained chondrogenic phenotype and formed hyaline cartilage. The avascular and hypoxia environment of the joint made it difficult for them to obtain quantified data for the anti-vascular effect of Chm-1. Compared with Klinger et al., we ectopically implanted Chm-1-transfected MSCs with coral scaffold. Our results indicated that Chm-1 is critical in inhibiting vascularization and maintaining the chondrogenic phenotype of tissue-engineered cartilage from

MSCs, even in a microenvironment suitable for tissue vascularization and ossification.

Several genes have been considered as targets to facilitate cartilage formation by autologous cells, including TGF-β1, BMPs, IGF, and FGF-2 [43, 44]. The results of the current experiment indicated that *Chm-1* could not only upregulate chondrogenic phenotype of MSCs but could also prevent vascularization. Consequently, this gene efficiently maintained the chondrogenic phenotype of engineered cartilage. We conclude that Chm-1 gene-




Fig. 5 Number of vessels in the specimens 1 month and 2 months post transplantation were statistically analyzed: **a** chondrocyte-coral composites; **b** chondrocytes and MSCs coseeded into natural coral scaffolds in a ratio of 1:1; **c** MSC-coral composites; and **d** T-MSC-coral composites. Vascular numbers of each specimen were counted per time point as the mean ± SD. Each bar represented four specimens (**P* < 0.05)

modified MSCs may hold great potential in tissue-engineering applications for cartilage regeneration.

Conclusions

In summary, we transfected rabbit MSCs with Ad5-Chm-1 and seeded these cells into a natural coral tissue-engineering scaffold to investigate the effect of exogenous Chm-1 expression in MSCs. We report that Chm-1 inhibited vascularization and maintained chondrocyte phenotype in vivo in Ad5-Chm-1-transfected MSCs. These results demonstrated that Chm-1-modified MSCs may be an optimized cell source for cartilage tissue engineering.

Abbreviations

Ad5-Chm-1: adenovirus-containing Chm-1 gene; bp: base pairs; Chm-1: Chondromodulin-1; FMMU: Four Military Medical University; GFP: green fluorescent protein; H & E: hematoxylin and eosin; MOI: multiplicity of infection; MSC: mesenchymal stem cell; MTS: Masson's trichrome staining; RT-PCR: reverse transcription-PCR; TB: toluidine blue; TGF- β : transforming growth factor beta; T-MSC: Ad5-Chm-1-transfected mesenchymal stem cell.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZYC, JW, JZ, and WL contributed to the study design, study performance, data collection, and preparation of the manuscript. JHC and HML contributed to the study performance, data analysis and interpretation, and preparation and revision of the manuscript. FLC contributed to the study design, preparation, and revision of the manuscript. ZYC and JW contributed equally to this work and should be considered coauthors. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the National Natural Science Foundation of P.R. China (No. 31271026, 31300797), Shaanxi Province and Ministry of Education Natural Science Foundation (No. 2013JQ4022, 13JS107), Natural Science Basic Research Plan in Shaanxi Province of China (No. 2013JC2-03), and the District-serving Scientific Research Program funded by Shaanxi Provincial Education Department (No. 15JF032).

Received: 17 December 2015 Revised: 1 February 2016

Accepted: 18 April 2016 Published online: 05 May 2016

References

- Yu H, Adesida AB, Jomha NM. Meniscus repair using mesenchymal stem cells—a comprehensive review. *Stem Cell Res Ther.* 2015;6:86.
- Zhang L, Hu J, Athanasiou KA. The role of tissue engineering in articular cartilage repair and regeneration. *Crit Rev Biomed Eng.* 2009;37:1–57.
- Gong Y, Su K, Lau TT, Zhou R, Wang DA. Microcavitary hydrogel-mediated phase transfer cell culture for cartilage tissue engineering. *Tissue Eng Part A.* 2010;16:3611–22.
- Jeong CG, Hollister SJ. Mechanical and biochemical assessments of three-dimensional poly(1,8-octanediol-co-citrate) scaffold pore shape and permeability effects on in vitro chondrogenesis using primary chondrocytes. *Tissue Eng Part A.* 2010;16:3759–68.
- Matricali GA, Dereymaeker GP, Luyten FP. Donor site morbidity after articular cartilage repair procedures: a review. *Acta Orthop Belg.* 2010;76:669–74.
- Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. *Tissue Eng.* 1998;4:415–28.
- Yoo JU, Barthel TS, Nishimura K, Solchaga L, Caplan AI, Goldberg VM, et al. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. *J Bone Joint Surg Am.* 1998;80:1745–57.
- Frenz DA, Liu W, Williams JD, Hatcher V, Galinovic-Schwartz V, Flanders KC, et al. Induction of chondrogenesis: requirement for synergistic interaction of basic fibroblast growth factor and transforming growth factor-beta. *Development.* 1994;120:415–24.
- Cao L, Yang F, Liu G, Yu D, Li H, Fan Q, et al. The promotion of cartilage defect repair using adenovirus mediated Sox9 gene transfer of rabbit bone marrow mesenchymal stem cells. *Biomaterials.* 2011;32:3910–20.
- He CX, Zhang TY, Miao PH, Hu ZJ, Han M, Tabata Y, et al. TGF- β 1 gene-engineered mesenchymal stem cells induce rat cartilage regeneration using nonviral gene vector. *Biotechnol Appl Biochem.* 2012;59:163–69.
- Katayama R, Wakitani S, Tsumaki N, Morita Y, Matsushita I, Gejo R, et al. Repair of articular cartilage defects in rabbits using CDMP1 gene-transfected autologous mesenchymal cells derived from bone marrow. *Rheumatology (Oxford).* 2004;43:980–85.
- Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, Ochs BG, et al. Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. *Arthritis Rheum.* 2006;54:3254–66.
- Mwale F, Girard-Lauriault PL, Wang HT, Lerouge S, Antoniou J, Wertheimer MR. Suppression of genes related to hypertrophy and osteogenesis in committed human mesenchymal stem cells cultured on novel nitrogen-rich plasma polymer coatings. *Tissue Eng.* 2006;12:2639–47.
- Chen WH, Lai MT, Wu AT, Wu CC, Gelovani JG, Lin CT. In vitro stagespecific chondrogenesis of mesenchymal stem cells committed to chondrocytes. *Arthritis Rheum.* 2009;60:450–9.
- Hendriks J, Riesle J, van Blitterswijk CA. Co-culture in cartilage tissue engineering. *J Tissue Eng Regen Med.* 2007;1:170–78.
- Bian L, Zhai DY, Mauck RL, Burdick JA. Coculture of human mesenchymal stem cells and articular chondrocytes reduces hypertrophy and enhances functional properties of engineered cartilage. *Tissue Eng Part A.* 2011;17:1137–45.
- Hwang NS, Varghese S, Puleo C, Zhang Z, Elisseeff J. Morphogenetic signals from chondrocytes promote chondrogenic and osteogenic differentiation of mesenchymal stem cells. *J Cell Physiol.* 2007;212:281–84.
- Wu L, Leijten JC, Georgi N, Post JN, van Blitterswijk CA, Karperien M. Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation. *Tissue Eng Part A.* 2011;17:1425–36.
- Kang N, Liu X, Guan Y, Wang J, Gong F, Yang X, et al. Effects of co-culturing BMSCs and articular chondrocytes on the elastic modulus and hypertrophy of tissue engineered cartilage. *Biomaterials.* 2012;33:4535–44.
- Meretoja VV, Dahlin RL, Kasper FK, Mikos AG. Enhanced chondrogenesis in co-cultures with articular chondrocytes and mesenchymal stem cells. *Biomaterials.* 2012;33:6362–69.
- Hiraki Y, Tanaka H, Inoue H, Kondo J, Kamizono A, Suzuki F. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. *Biochem Biophys Res Commun.* 1991;175:971–77.
- Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C, et al. Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. *J Biol Chem.* 1997;272:32419–26.
- Funaki H, Sawaguchi S, Yaoeda K, Koyama Y, Yaoita E, Funaki S, et al. Expression and localization of angiogenic inhibitory factor, chondromodulin-I, in adult rat eye. *Invest Ophthalmol Vis Sci.* 2001;42:1193–200.
- Hiraki Y, Mitsui K, Endo N, Takahashi K, Hayami T, Inoue H, et al. Molecular cloning of human chondromodulin-I, a cartilage-derived growth modulating factor, and its expression in Chinese hamster ovary cells. *Eur J Biochem.* 1999;260:869–78.
- Blanke M, Carl HD, Klinger P, Swoboda B, Hennig F, Gelse K. Transplanted chondrocytes inhibit endochondral ossification within cartilage repair tissue. *Calcif Tissue Int.* 2009;85:421–33.
- Dong QS, Shang HT, Wu W, Chen FL, Zhang JR, Guo JP, et al. Prefabrication of axial vascularized tissue engineering coral bone by an arteriovenous loop: a better model. *Mater Sci Eng C Mater Biol Appl.* 2012;32:1536–41.
- Cai L, Wang Q, Gu C, Wu J, Wang J, Kang N, et al. Vascular and micro-environmental influences on MSC-coral hydroxyapatite construct-based bone tissue engineering. *Biomaterials.* 2011;32:8497–505.
- Geng W, Ma D, Yan X, Liu L, Cui J, Xie X, et al. Engineering tubular bone using mesenchymal stem cell sheets and coral particles. *Biochem Biophys Res Commun.* 2013;433:595–601.
- Wu W, Cheng X, Zhao Y, Chen F, Feng X, Mao T. Tissue engineering of trachea-like cartilage grafts by using chondrocyte macroaggregate: experimental study in rabbits. *Artif Organs.* 2007;31:826–34.
- Chen F, Chen S, Tao K, Feng X, Liu Y, Lei D, et al. Marrow-derived osteoblasts seeded into porous natural coral to prefabricate a vascularised bone graft in

- the shape of a human mandibular ramus: experimental study in rabbits. *Br J Oral Maxillofac Surg.* 2004;42:532–37.
31. Peach MS, James R, Toti US, Deng M, Morozowich NL, Allcock HR, et al. Polyphosphazene functionalized polyester fiber matrices for tendon tissue engineering: in vitro evaluation with human mesenchymal stem cells. *Biomed Mater.* 2012;7:45016.
 32. Facchiano F, Fernandez E, Mancarella S, Maira G, Miscusi M, D'Arcangelo D, et al. Promotion of regeneration of corticospinal tract axons in rats with recombinant vascular endothelial growth factor alone and combined with adenovirus coding for this factor. *J Neurosurg.* 2002;97:161–68.
 33. Mueller MB, Tuan RS. Functional characterization of hypertrophy in chondrogenesis of human mesenchymal stem cells. *Arthritis Rheum.* 2008;58:1377–88.
 34. Liu X, Sun H, Yan D, Zhang L, Lv X, Liu T, et al. In vivo ectopic chondrogenesis of BMSCs directed by mature chondrocytes. *Biomaterials.* 2010;31:9406–14.
 35. Dietz UH, Ziegelmeier G, Bittner K, Bruckner P, Balling R. Spatio-temporal distribution of chondromodulin-I mRNA in the chicken embryo: expression during cartilage development and formation of the heart and eye. *Dev Dyn.* 1999;216:233–43.
 36. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N, et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. *Nat Med.* 2006;12:1151–59.
 37. Shukunami C, Takimoto A, Miura S, Nishizaki Y, Hiraki Y. Chondromodulin-I and tenomodulin are differentially expressed in the avascular mesenchyme during mouse and chick development. *Cell Tissue Res.* 2008;332:111–22.
 38. Shukunami C, Iyama K, Inoue H, Hiraki Y. Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. *Int J Dev Biol.* 1999;43:39–49.
 39. Tsai AC, Pan SL, Sun HL, Wang CY, Peng CY, Wang SW, et al. CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation. *J Biol Chem.* 2010;285:5497–506.
 40. Mera H, Kawashima H, Yoshizawa T, Ishibashi O, Ali MM, Hayami T, et al. Chondromodulin-1 directly suppresses growth of human cancer cells. *BMC Cancer.* 2009;9:166.
 41. Shukunami C, Hiraki Y. Chondromodulin-I and tenomodulin: the negative control of angiogenesis in connective tissue. *Curr Pharm Des.* 2007;13:2101–12.
 42. Henderson IJ, La Valette DP. Subchondral bone overgrowth in the presence of full-thickness cartilage defects in the knee. *Knee.* 2005;12:435–40.
 43. Han F, Zhou F, Yang X, Zhao J, Zhao Y, Yuan X. A pilot study of conically graded chitosan-gelatin hydrogel/PLGA scaffold with dual-delivery of TGF-beta1 and BMP-2 for regeneration of cartilage-bone interface. *J Biomed Mater Res B Appl Biomater.* 2015;103:1344–53.
 44. Orth P, Kaul G, Cucchiariini M, Zurakowski D, Menger MD, Kohn D, et al. Transplanted articular chondrocytes co-overexpressing IGF-I and FGF-2 stimulate cartilage repair in vivo. *Knee Surg Sports Traumatol Arthrosc.* 2011;19:2119–30.
 45. Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. *Biomaterials.* 2005;26:5474–91.
 46. Hou R, Chen F, Yang Y, Cheng X, Gao Z, Yang HO, et al. Comparative study between coral-mesenchymal stem cells-rhBMP-2 composite and auto-bone-graft in rabbit critical-sized cranial defect model. *J Biomed Mater Res A.* 2007;80:85–93.
 47. Klinger P, Surmann-Schmitt C, Brem M, Swoboda B, Distler JH, Carl HD, et al. Chondromodulin 1 stabilizes the chondrocyte phenotype and inhibits endochondral ossification of porcine cartilage repair tissue. *Arthritis Rheum.* 2011;63:2721–31.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

